Defibrotide Treatment for Hepatic Veno-occlusive Disease after Umbilical Cord Blood Transplantation.
- Author:
Jun Sun YI
1
;
Hoon KOOK
;
Ha Young NOH
;
Hee Jo BAEK
;
So Youn KIM
;
Kyoung Ran SOHN
;
Ik Sun CHOI
;
Hyun Jin PARK
;
Tai Ju HWANG
Author Information
1. Department of Pediatrics, Chonnam National University Medical School, Gwangju, Korea. hoonkook@chonnam.ac.kr
- Publication Type:Case Report ; Clinical Trial
- Keywords:
Venoocclussive disease;
Umblical cord blood transplantation;
Defibrotide
- MeSH:
Bone Marrow Transplantation;
Child;
Child, Preschool;
Empathy;
Fetal Blood*;
Hepatic Veno-Occlusive Disease*;
Humans;
Liver;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Umbilical Cord*
- From:Korean Journal of Pediatric Hematology-Oncology
2004;11(1):92-96
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Veno-occlusive disease (VOD) of the liver is a life-threatening complication occurring early after blood or bone marrow transplantation (BMT). Effective treatment has not been established in case of severe forms of VOD. Defibrotide, a single-stranded polydeoxyribonucleotide, has been used on a compassionate basis in recent clinical trials with promising results. We report here with the first Korean experience of using defibrotide for the treatment of hepatic VOD occurring after unrelated umbilical cord blood transplant in a 2-year-old child with acute lymphoblastic leukemia. Defibrotide was administered for 23 days without any significant side effects with resolution of signs and symptoms of VOD.
